We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

177 hedge funds and large institutions have $944M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 67 increasing their positions, 53 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

26% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 53

8% more funds holding

Funds holding: 164177 (+13)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

3% less capital invested

Capital invested by funds: $972M → $944M (-$28.6M)

80% less call options, than puts

Call options by funds: $85K | Put options by funds: $434K

Holders
177
Holders Change
+13
Holders Change %
+7.93%
% of All Funds
2.55%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
27
Increased
67
Reduced
53
Closed
14
Calls
$85K
Puts
$434K
Net Calls
-$349K
Net Calls Change
-$898K
Name Holding Trade Value Shares
Change
Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$7.97M +$1.81M +117,721 +30%
Deutsche Bank
27
Deutsche Bank
Germany
$7.67M +$18.1K +1,174 +0.2%
Jacobs Levy Equity Management
28
Jacobs Levy Equity Management
New Jersey
$7.42M +$738K +47,936 +11%
PAM
29
Panagora Asset Management
Massachusetts
$6.56M +$2.79M +181,219 +77%
Two Sigma Advisers
30
Two Sigma Advisers
New York
$6.31M -$480K -31,200 -7%
UBS AM
31
UBS AM
Illinois
$6.27M -$23.1K -1,504 -0.4%
SSA
32
Schonfeld Strategic Advisors
New York
$5.65M +$1.23M +79,756 +29%
Norges Bank
33
Norges Bank
Norway
$5.54M
Two Sigma Investments
34
Two Sigma Investments
New York
$4.91M -$1.47M -95,506 -23%
Walleye Capital
35
Walleye Capital
New York
$4.63M -$576K -37,403 -11%
EIM
36
Essex Investment Management
Massachusetts
$4.54M +$4.44M +288,635 New
Connor, Clark & Lunn Investment Management (CC&L)
37
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$4.39M +$429K +27,902 +11%
LCM
38
Laurion Capital Management
New York
$4.32M +$4.23M +274,634 New
CSS
39
Cubist Systematic Strategies
Connecticut
$3.95M -$423K -27,496 -10%
Qube Research & Technologies (QRT)
40
Qube Research & Technologies (QRT)
United Kingdom
$3.81M +$1.88M +122,296 +102%
Bank of America
41
Bank of America
North Carolina
$3.51M +$2.11M +136,937 +159%
Rafferty Asset Management
42
Rafferty Asset Management
New York
$3.43M +$1.21M +78,655 +56%
Public Sector Pension Investment Board (PSP Investments)
43
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$3.37M
Citigroup
44
Citigroup
New York
$3.02M +$1.99M +129,269 +207%
Bank of New York Mellon
45
Bank of New York Mellon
New York
$3.01M -$167K -10,882 -5%
Voloridge Investment Management
46
Voloridge Investment Management
Florida
$2.86M -$187K -12,170 -6%
GTC
47
Ghost Tree Capital
New York
$2.78M -$746K -48,487 -22%
UBS Group
48
UBS Group
Switzerland
$2.62M +$617K +40,115 +32%
ECM
49
ExodusPoint Capital Management
New York
$2.53M +$674K +43,758 +37%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
50
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$2.39M

DCPH Hedge Fund Activity: Q1 2024 in Review

177 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q1 2024, worth a combined $944M — down 2.9% from $972M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new DCPH positions and 14 closed out — a net gain of 13 holders — while 67 added to existing stakes and 53 trimmed.

The largest buyer was Armistice Capital, adding an estimated $10.8M. The largest seller was Morgan Stanley, cutting an estimated $47.6M.

  • 177 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q1 2024, up from 164 in Q4 2023.
  • Funds reported $944M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q1 2024, down 2.9% quarter-over-quarter.
  • 27 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q1 2024 and 14 closed out, a net change of +13 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q1 2024 was Armistice Capital, an estimated $10.8M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q1 2024 was Morgan Stanley, an estimated $47.6M sold.

Based on aggregated 13F filings for Q1 2024.